Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
News|Articles|January 2, 2021
- Pharmaceutical Technology-01-02-2021
- Volume 45
- Issue 1
Ultra-Low-Temperature Freezers for COVID-19 Vaccines
Boreas from Telstar are -86 ºC ultra-low-temperature freezers developed to house COVID-19 vaccines.
Boreas from Telstar are -86 ºC ultra-low-temperature freezers developed to house COVID-19 vaccines. Designed with enhanced robustness, efficiency, and ergonomics, the freezers come equipped with vacuum panels for high levels of insulation to uphold a temperature of -80 ºC with ambient temperatures up to +28 ºC. Instead of using polyurethane foam like many standard freezers, Boreas feature a thinner inner insulation for an enlarged storage capacity of up to 30%. Additionally, the freezers use high purity natural refrigerant CFC free gases that contribute to environment preservation.
Articles in this issue
almost 6 years ago
Bringing Bio/Pharma’s “New Normal” Into Focusalmost 6 years ago
The Outlook for a Year of Changealmost 6 years ago
Compensation Does Not Necessarily Align With Job Satisfactionalmost 6 years ago
Talent-Driven Market for Laboratory Techniciansalmost 6 years ago
ECHA’s Microplastics Use Restriction—Impact on Pharmaceuticalsalmost 6 years ago
FDA Ends 2020 with High Drug Approval Ratealmost 6 years ago
Overcoming Biologic Drug Formulation Hurdlesalmost 6 years ago
Choosing a Cleanroom Infrastructure Technologyalmost 6 years ago
COVID-19 Vaccine Distribution: Preparing for the Unexpectedalmost 6 years ago
FDA Inspections Remain Stalled During the COVID-19 PandemicRelated to this article
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
Germany’s Medical Biotechnology Sector is Flourishing
4
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
5